Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes,

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.